Evaluation of the Feasibility of Using Augmented Reality in Laparoscopic Surgery, by a Clinical Study During Gynecological Laparoscopic Surgical Procedures. (ENDORA2)
Launched by UNIVERSITY HOSPITAL, CLERMONT-FERRAND · Sep 28, 2023
Trial Information
Current as of August 22, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial, called ENDORA2, is exploring the use of Augmented Reality (AR) technology during laparoscopic surgery for women who have benign tumors in the uterus, such as myomas or adenomyomas. AR allows surgeons to see virtual images on top of what they view through their instruments, which can help them locate and remove these tumors more easily and safely. The trial aims to find out if using this technology makes the surgery more comfortable for the surgeon and improves their ability to see the area they are working on.
To participate in this study, women between the ages of 18 and 84 who are scheduled for surgery to remove uterine tumors might be eligible. They need to have health insurance and agree to take part in the study after being fully informed about it. Participants can expect to undergo laparoscopic surgery with the added use of augmented reality tools. The trial is currently looking for volunteers, and it is important to note that certain individuals, such as those with specific medical conditions or those who cannot attend follow-ups, may not qualify for the study.
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Aged between 18 (included) and 84 (included),
- • Patient with intrauterine myoma, with indication for surgical management by laparoscopic myomectomy, or uterine pathology with indication for surgical management by laparoscopic hysterectomy,
- • Patient affiliated or beneficiary of a health insurance scheme,
- • Patient agreeing to participate in the study after having received the written information document and signed the consent form.
- Exclusion Criteria:
- • Patients under 18 or over 84 years of age,
- • Patients with contraindications to MRI (pacemaker, ocular metal splinters, etc.),
- • Impossibility of planned surgery,
- • Patient with endometrial cancer contraindicating laparoscopic surgery,
- • Known pregnant or breast-feeding patient,
- • Patient of legal age, under guardianship or curatorship,
- • Patients whose regular follow-up is impossible for geographical, psychological, family or social reasons (these reasons will be collected).
About University Hospital, Clermont Ferrand
The University Hospital of Clermont-Ferrand is a leading academic medical institution dedicated to advancing healthcare through innovative research and clinical trials. Renowned for its multidisciplinary approach, the hospital integrates cutting-edge scientific inquiry with patient care, fostering an environment that promotes collaboration among healthcare professionals, researchers, and academic partners. With a strong commitment to improving patient outcomes, the institution actively engages in a wide array of clinical studies, ranging from early-phase trials to large-scale interventions, aimed at addressing critical health challenges and enhancing treatment modalities. Its state-of-the-art facilities and expertise make it a pivotal contributor to clinical research in the region and beyond.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Avignon, , France
Clermont Ferrand, , France
Saint étienne, , France
Patients applied
Trial Officials
Pauline CHAUVET
Principal Investigator
pchauvet@chu-clermontferrand.fr
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported